News | May 25, 2026
Anupam Rasayan to acquire 43.3%–48.2% equity stake in Bliss GVS Pharma
The acquisition marks Anupam Rasayan’s strategic entry into the pharmaceutical formulations segment
The acquisition marks Anupam Rasayan’s strategic entry into the pharmaceutical formulations segment
If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings
Kheruka has played a key role in transforming Borosil into a diversified, international consumer-focused enterprise
Surya to lead medical governance, patient safety, clinical excellence, and quality assurance initiatives across the organization’s pan-India network.
Q4 FY26 PAT jumps 44% to Rs. 271 crore, supported by acquisitions, specialty expansion, and diagnostics momentum
Biologics manufacturing veteran brings over two decades of expertise in biosimilars, GMP operations, and large-scale biopharmaceutical manufacturing
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
Dr. Upadhyay brings over 25 years of global leadership experience across life sciences, regulated manufacturing, diagnostics, and research-led environments
Sheshadri brings with him extensive leadership experience spanning healthcare, diagnostics, telecom, and consumer goods industries
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
Subscribe To Our Newsletter & Stay Updated
